Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John L Cameron

Showing results (261-270 of 286) with videos related to

Pageof 29
Sort By:
Annals of Surgery|July 14, 2020
Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic CancerToni T Seppälä, Jacquelyn W Zimmerman, Elisabetta Sereni, et al.
International Journal of Radiation Oncology, Biology, Physics|June 19, 2013
Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancerJoseph M Herman, Katherine Y Fan, Aaron T Wild, et al.
JAMA Surgery|May 26, 2018
Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver CancerGeorgios Antonios Margonis, Stefan Buettner, Nikolaos Andreatos, et al.
Journal of Radiation Oncology|March 11, 2015
Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor-vessel relationshipsAvani S Dholakia, Amy Hacker-Prietz, Aaron T Wild, et al.
Annals of Surgery|December 6, 2019
Intraductal Papillary Mucinous Neoplasms: Have IAP Consensus Guidelines Changed our Approach?: Results from a Multi-institutional StudyAlessandra Pulvirenti, Georgios A Margonis, Vicente Morales-Oyarvide, et al.
Surgery|November 14, 2021
Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapyShimpei Maeda, Michael A Mederos, Akhil Chawla, et al.
The American Journal of Pathology|April 24, 2018
Immunolabeling of Cleared Human Pancreata Provides Insights into Three-Dimensional Pancreatic Anatomy and PathologyMichaël Noë, Neda Rezaee, Kaushal Asrani, et al.
Gut|March 4, 2018
IPMNs with co-occurring invasive cancers: neighbours but not always relativesMatthäus Felsenstein, Michaël Noë, David L Masica, et al.
Annals of Surgery|January 13, 2017
Development and Validation of a Multi-institutional Preoperative Nomogram for Predicting Grade of Dysplasia in Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas: A Report from The Pancreatic Surgery ConsortiumMarc A Attiyeh, Carlos Fernández-Del Castillo, Mohammad Al Efishat, et al.
Cancer Research|April 9, 2009
Genetic mutations associated with cigarette smoking in pancreatic cancerAmanda Blackford, Giovanni Parmigiani, Thomas W Kensler, et al.
Pageof 29

Showing results (261-270 of 286) with videos related to

Sort By:
Pageof 29
Annals of Surgery|July 14, 2020
Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic CancerToni T Seppälä, Jacquelyn W Zimmerman, Elisabetta Sereni, et al.
International Journal of Radiation Oncology, Biology, Physics|June 19, 2013
Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancerJoseph M Herman, Katherine Y Fan, Aaron T Wild, et al.
JAMA Surgery|May 26, 2018
Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver CancerGeorgios Antonios Margonis, Stefan Buettner, Nikolaos Andreatos, et al.
Journal of Radiation Oncology|March 11, 2015
Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor-vessel relationshipsAvani S Dholakia, Amy Hacker-Prietz, Aaron T Wild, et al.
Annals of Surgery|December 6, 2019
Intraductal Papillary Mucinous Neoplasms: Have IAP Consensus Guidelines Changed our Approach?: Results from a Multi-institutional StudyAlessandra Pulvirenti, Georgios A Margonis, Vicente Morales-Oyarvide, et al.
Surgery|November 14, 2021
Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapyShimpei Maeda, Michael A Mederos, Akhil Chawla, et al.
The American Journal of Pathology|April 24, 2018
Immunolabeling of Cleared Human Pancreata Provides Insights into Three-Dimensional Pancreatic Anatomy and PathologyMichaël Noë, Neda Rezaee, Kaushal Asrani, et al.
Gut|March 4, 2018
IPMNs with co-occurring invasive cancers: neighbours but not always relativesMatthäus Felsenstein, Michaël Noë, David L Masica, et al.
Annals of Surgery|January 13, 2017
Development and Validation of a Multi-institutional Preoperative Nomogram for Predicting Grade of Dysplasia in Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas: A Report from The Pancreatic Surgery ConsortiumMarc A Attiyeh, Carlos Fernández-Del Castillo, Mohammad Al Efishat, et al.
Cancer Research|April 9, 2009
Genetic mutations associated with cigarette smoking in pancreatic cancerAmanda Blackford, Giovanni Parmigiani, Thomas W Kensler, et al.
Pageof 29